Copenhagen, 22 July 2026 — EBM Newsdesk Analysis — By Anthony Gill
Novo Nordisk has sued Eli Lilly in a New Jersey federal court, accusing its American rival of running advertising that is “maliciously and deceptively false” about how their weight-loss drugs compare. The detail that gives the case away is what Novo is asking for: not damages first, but an order forcing Lilly to pull the ads and run a corrective campaign admitting the comparison was wrong. Companies winning a market do not usually need a judge to fix the scoreboard. This is the $480bn champion that lost three-quarters of its value reaching for the one weapon it has left.
The legal claim is narrow and, on its own terms, not unreasonable. What matters for European business is what drives a Danish giant to sue rather than sell. That is a story about losing, and about how quickly a dominant position can evaporate.
Join The European Business Briefing
New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.
SubscribeThe complaint, in plain terms
Novo’s argument is about dosage. Lilly’s ads compare the highest approved dose of its drugs, Zepbound for obesity and Mounjaro for diabetes, against lower doses of Novo’s Wegovy and Ozempic. On those numbers, Lilly’s drugs win.
Novo says the comparison is out of date. In March it launched a higher, 7.2-milligram dose of Wegovy, which it says produces average weight loss of around 47 pounds — close to what Zepbound achieved in Lilly’s own trial. The ads, Novo argues, ignore the newer dose and leave viewers with the false impression that Lilly’s medicine is simply better.
There is a catch Novo cannot escape. The only head-to-head trial that directly pits the two drugs against each other was run by Lilly last year, and Zepbound won it. Novo’s higher dose was approved afterwards, so no trial has ever compared the current best versions of each drug side by side. Novo is asking a court to stop Lilly citing the one direct comparison that exists, on the grounds that newer indirect data has caught up. That is a harder case to win than the press release suggests.
Lilly’s response was blunt. Rather than compete on the merits, it said, Novo is asking a court to stop it communicating the results of a trial it actually ran. Lilly says it will defend the suit vigorously.
Why Novo is really in court
Step back and the lawsuit reads as a symptom. Two years ago Novo Nordisk was the most valuable company in Europe, worth more than LVMH or ASML, on the back of Ozempic and Wegovy. It got there first. Then Lilly arrived with a drug that worked better, caught up, and took the lead in US sales.
Novo has spent the time since trying to claw back ground. It replaced its chief executive. It issued profit warnings. It launched an oral version of Wegovy that has sold well. The high-dose injection at the centre of this lawsuit is part of the same fightback. Suing over Lilly’s advertising is the latest move, and it is a defensive one.
The prize explains the aggression. The global market for obesity drugs is on track to be worth more than $120bn a year by 2030. In a market that large, a few points of share are worth billions, and the advertising that shapes which drug a patient asks for is a battleground in itself. Both firms spend heavily on it.
What it signals
For European business the case is a reminder of how fragile a lead built on a single product category can be. Novo’s rise made it a symbol, proof that a European firm could out-compete the American giants in a field that mattered. Its fall has been just as fast, and it has happened not through regulation or politics but through a straightforward loss to a better product.
That should trouble anyone cheering for European champions. The continent’s biggest recent success story is now fighting a rearguard action in an American courtroom, trying to stop a rival telling the market it won.
The verdict
Novo may have a point about the dosage. It may even win a narrow order forcing Lilly to update its ads. But a company that has to sue to correct the impression that it is losing has already conceded the more important argument. The lawsuit will not decide who leads the obesity market. Better drugs and better marketing will, and on both counts Novo is currently behind. This is the sound of a former champion reaching for its lawyers because the science and the sales are no longer doing the work.
